Literature DB >> 20102920

Mutation-specific risk in two genetic forms of type 3 long QT syndrome.

Judy F Liu1, Arthur J Moss, Christian Jons, Jesaia Benhorin, Peter J Schwartz, Carla Spazzolini, Lia Crotti, Michael J Ackerman, Scott McNitt, Jennifer L Robinson, Ming Qi, Ilan Goldenberg, Wojciech Zareba.   

Abstract

The clinical course of patients with 2 relatively common long QT syndrome type 3 mutations has not been well described. In the present study, we investigated the mutational-specific risk in patients with deletional (DeltaKPQ) and missense (D1790G) mutations involving the SCN5A gene. The study population involved 50 patients with the DeltaKPQ mutation and 35 patients with the D1790G mutation. The cumulative probability of a first cardiac event (syncope, aborted cardiac arrest, or long QT syndrome-related sudden death) was evaluated using the Kaplan-Meier method. The Cox proportional hazards survivorship model was used to determine the independent contribution of clinical and genetic factors to the first occurrence of cardiac events from birth through 40 years of age. The Andersen-Gill proportional intensity regression model was used to analyze the factors associated with recurrent syncope. Patients with a DeltaKPQ mutation had a significantly greater probability of a first cardiac event from birth through 40 years of age (34%) than those with the D1790G mutation (20%; p <0.001). Multivariate analysis demonstrated an increased risk of cardiac events among DeltaKPQ carriers compared to D1790G carriers (hazard ratio 2.42, p <0.0001) after adjustment for gender and QTc duration. Patients with DeltaKPQ mutations also had an increased risk of recurrent syncope (hazard ratio 5.20, p <0.001). In conclusion, the clinical course of patients with long QT syndrome type with DeltaKPQ mutations was shown to be more virulent than those with D1790G mutations, and this effect was independent of QTc duration. The findings highlight the importance of knowing the specific mutation in risk stratification of patients with long QT syndrome type 3. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20102920      PMCID: PMC2813568          DOI: 10.1016/j.amjcard.2009.08.676

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  22 in total

1.  Arrhythmogenic mechanism of an LQT-3 mutation of the human heart Na(+) channel alpha-subunit: A computational analysis.

Authors:  X H Wehrens; H Abriel; C Cabo; J Benhorin; R S Kass
Journal:  Circulation       Date:  2000-08-01       Impact factor: 29.690

2.  All LQT3 patients need an ICD: true or false?

Authors:  Peter J Schwartz; Carla Spazzolini; Lia Crotti
Journal:  Heart Rhythm       Date:  2008-10-15       Impact factor: 6.343

3.  Biophysical phenotypes of SCN5A mutations causing long QT and Brugada syndromes.

Authors:  G Baroudi; M Chahine
Journal:  FEBS Lett       Date:  2000-12-29       Impact factor: 4.124

4.  Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias.

Authors:  P J Schwartz; S G Priori; C Spazzolini; A J Moss; G M Vincent; C Napolitano; I Denjoy; P Guicheney; G Breithardt; M T Keating; J A Towbin; A H Beggs; P Brink; A A Wilde; L Toivonen; W Zareba; J L Robinson; K W Timothy; V Corfield; D Wattanasirichaigoon; C Corbett; W Haverkamp; E Schulze-Bahr; M H Lehmann; K Schwartz; P Coumel; R Bloise
Journal:  Circulation       Date:  2001-01-02       Impact factor: 29.690

5.  Abrupt rate accelerations or premature beats cause life-threatening arrhythmias in mice with long-QT3 syndrome.

Authors:  D Nuyens; M Stengl; S Dugarmaa; T Rossenbacker; V Compernolle; Y Rudy; J F Smits; W Flameng; C E Clancy; L Moons; M A Vos; M Dewerchin; K Benndorf; D Collen; E Carmeliet; P Carmeliet
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

6.  The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.

Authors:  S G Priori; C Napolitano; P J Schwartz; R Bloise; L Crotti; E Ronchetti
Journal:  Circulation       Date:  2000-08-29       Impact factor: 29.690

7.  Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?

Authors:  J Benhorin; R Taub; M Goldmit; B Kerem; R S Kass; I Windman; A Medina
Journal:  Circulation       Date:  2000-04-11       Impact factor: 29.690

8.  Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.

Authors:  J R Windle; R C Geletka; A J Moss; W Zareba; D L Atkins
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-04       Impact factor: 1.468

9.  Molecular mechanism for an inherited cardiac arrhythmia.

Authors:  P B Bennett; K Yazawa; N Makita; A L George
Journal:  Nature       Date:  1995-08-24       Impact factor: 49.962

10.  Association of long QT syndrome loci and cardiac events among patients treated with beta-blockers.

Authors:  Silvia G Priori; Carlo Napolitano; Peter J Schwartz; Massimiliano Grillo; Raffaella Bloise; Elena Ronchetti; Cinzia Moncalvo; Chiara Tulipani; Alessia Veia; Georgia Bottelli; Janni Nastoli
Journal:  JAMA       Date:  2004-09-15       Impact factor: 56.272

View more
  10 in total

Review 1.  Genotype-specific risk stratification and management of patients with long QT syndrome.

Authors:  Alon Barsheshet; Olena Dotsenko; Ilan Goldenberg
Journal:  Ann Noninvasive Electrocardiol       Date:  2013-11-08       Impact factor: 1.468

Review 2.  Genetics of sudden cardiac death.

Authors:  Alon Barsheshet; Andrew Brenyo; Arthur J Moss; Ilan Goldenberg
Journal:  Curr Cardiol Rep       Date:  2011-10       Impact factor: 2.931

3.  Light phase-restricted feeding slows basal heart rate to exaggerate the type-3 long QT syndrome phenotype in mice.

Authors:  Elizabeth A Schroder; Don E Burgess; Cody L Manning; Yihua Zhao; Arthur J Moss; Abhijit Patwardhan; Claude S Elayi; Karyn A Esser; Brian P Delisle
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-10-24       Impact factor: 4.733

Review 4.  Molecular Pathophysiology of Congenital Long QT Syndrome.

Authors:  M S Bohnen; G Peng; S H Robey; C Terrenoire; V Iyer; K J Sampson; R S Kass
Journal:  Physiol Rev       Date:  2017-01       Impact factor: 37.312

Review 5.  Genetic etiology and evaluation of sudden cardiac death.

Authors:  Elena Dolmatova; Saagar Mahida; Patrick T Ellinor; Steven A Lubitz
Journal:  Curr Cardiol Rep       Date:  2013-08       Impact factor: 2.931

Review 6.  Beyond the Electrocardiogram: Mutations in Cardiac Ion Channel Genes Underlie Nonarrhythmic Phenotypes.

Authors:  Thomas M Roston; Taylor Cunningham; Anna Lehman; Zachary W Laksman; Andrew D Krahn; Shubhayan Sanatani
Journal:  Clin Med Insights Cardiol       Date:  2017-03-16

7.  Clinical and molecular genetic risk determinants in adult long QT syndrome type 1 and 2 patients : Koponen et al. Follow-up of adult LQTS patients.

Authors:  Mikael Koponen; Aki S Havulinna; Annukka Marjamaa; Annukka M Tuiskula; Veikko Salomaa; Päivi J Laitinen-Forsblom; Kirsi Piippo; Lauri Toivonen; Kimmo Kontula; Matti Viitasalo; Heikki Swan
Journal:  BMC Med Genet       Date:  2018-04-05       Impact factor: 2.103

8.  Diagnostic yield and variant reassessment in the genes encoding Nav1.5 channel in Russian patients with Brugada syndrome.

Authors:  Elena Zaklyazminskaya; Anna Shestak; Dmitry Podolyak; Vera Komoliatova; Leonid Makarov; Anna Novitskaya; Amiran Revishvili
Journal:  Front Pharmacol       Date:  2022-08-24       Impact factor: 5.988

Review 9.  The congenital long QT syndrome Type 3: An update.

Authors:  Andrés Ricardo Pérez-Riera; Raimundo Barbosa-Barros; Rodrigo Daminello Raimundo; Marianne Penachini da Costa de Rezende Barbosa; Isabel Cristina Esposito Sorpreso; Luiz Carlos de Abreu
Journal:  Indian Pacing Electrophysiol J       Date:  2017-10-31

10.  Next generation diagnostics in inherited arrhythmia syndromes : a comparison of two approaches.

Authors:  James S Ware; Shibu John; Angharad M Roberts; Rachel Buchan; Sungsam Gong; Nicholas S Peters; David O Robinson; Anneke Lucassen; Elijah R Behr; Stuart A Cook
Journal:  J Cardiovasc Transl Res       Date:  2012-09-07       Impact factor: 4.132

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.